Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Bioorg Med Chem. 2013 Jan 1;21(1):28-41. doi: 10.1016/j.bmc.2012.11.006. Epub 2012 Nov 15.
A series of piperazine ureas was designed, synthesized, and evaluated for their potential as novel orally available fatty acid amide hydrolase (FAAH) inhibitors that are therapeutically effective against pain. We carried out an optimization study of the lead compound 3 to improve its DMPK profile as well as in vitro potency. We identified the thiazole compound 60j with potent inhibitory activity, high brain permeability, and good bioavailability. Compound 60j showed a potent and dose-dependent anti-nociceptive effect in the acetic acid-induced writhing test in mice.
我们设计、合成了一系列哌嗪脲类化合物,并对其作为新型口服脂肪酸酰胺水解酶(FAAH)抑制剂的潜力进行了评估,这些抑制剂在治疗疼痛方面具有疗效。我们对先导化合物 3 进行了优化研究,以改善其 DMPK 特性和体外活性。我们发现噻唑类化合物 60j 具有很强的抑制活性、较高的脑渗透性和良好的生物利用度。化合物 60j 在小鼠醋酸扭体试验中表现出强大的、剂量依赖性的抗伤害作用。